# Intensity Therapeutics Inc. (INTS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $5M  
**Price:** $3.74 (+0.81%)

> Intensity Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative cancer treatments that enhance the effectiveness of conventional therapies. The company's primary focus is on discovering and advancing novel, proprietary immune-based drug products to combat solid tumors. Utilizing its unique DfuseRxSM technology platform, Intensity Therapeutics integrates chemotherapy with immunotherapy to create a localized treatment that stimulates a systemic, adaptive immune response. This approach aims to increase the overall survival rate of cancer patients while minimizing side effects. Intensity Therapeutics primarily targets the oncology sector, with applications in various cancer types including breast, colorectal, and liver cancers. Highlighted by its ongoing clinical trials, the company plays a significant role in advancing medical research and development in the biotech industry. Intensity Therapeutics Inc. demonstrates a strong commitment to pioneering new frontiers in cancer treatment, contributing significantly to both scientific innovation and patient care within the healthcare market.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$12M | -$12M | $-8.56 |
| 2024 | — | — | -$17M | -$16M | $-29.25 |
| 2023 | — | — | -$8M | -$11M | $-1.38 |
| 2022 | — | — | -$8M | -$8M | $-2.19 |
| 2021 | — | — | -$8M | -$8M | $-0.60 |
| 2020 | — | — | -$6M | -$6M | $-0.33 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $14M | $2M | $12M | $12M | $79,000 |
| 2024 | $5M | $2M | $3M | $3M | $110,000 |
| 2023 | $17M | $4M | $13M | $9M | $138,000 |
| 2022 | $2M | $17M | -$15M | $1M | — |
| 2021 | $5M | $14M | -$9M | $5M | $143,569 |
| 2020 | $10M | $12M | -$2M | $9M | $326,255 |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$9M | — | -$9M |
| 2024 | -$16M | — | -$15M |
| 2023 | -$7M | — | -$7M |
| 2022 | -$6M | — | -$5M |
| 2021 | -$7M | — | -$7M |
| 2020 | -$6M | — | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/INTS)